NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
Symphogen A/S
Peking University
Novartis
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center